RDS/peripherin gene mutations are frequent causes of central retinal dystrophies

Susanne Kohl, Margot Christ-Adler, Eckart Apfelstedt-Sylla, Ulrich Kellner, Anja Eckstein, Eberhart Zrenner, Bernd Wissinger

Abstract

Patients from 76 independent families with various forms of mostly central retinal dystrophies were screened for mutations in the RDS/peripherin gene by means of SSCP analysis and direct DNA sequencing. Two nonsense mutations (Gln239ter, Tyr285ter), five missense mutations (Arg172Trp, Lys197Glu, Gly208Arg, Trp246Arg, Ser289Leu), and one single base insertion (Gly208insG), heterozygous in all cases, were detected. Only one of these mutations, Arg172Trp, has been reported previously. Co segregation of the mutation with the disease phenotype could be established in selected families. Other missense mutations were excluded from a panel of 55-75 control subjects. The patients showed remarkable variation in phenotype and disease expression not only between cases with different mutations but also between affected members of the same family. This study indicates that RDS/peripherin mutations are a frequent cause of various types of central retinal dystrophies and that the RDS/peripherin gene exhibits a broad spectrum of allelic mutations. Comparative analysis of known mutations allowed us to hypothesise that the deleterious effect of RDS/peripherin gene mutations is the result of different molecular mechanisms. (J Med Genet 1997;34:620-626)

Keywords: RDS/peripherin; retinal dystrophies; mutation analysis

The RDS (retinal degeneration slow)/peripherin gene encodes a disc membrane associated glycoprotein in vertebrate photoreceptor outer segments. It has been shown that the RDS/peripherin polypeptide is preferentially located at the rim of the disc membranes and a role in the structural organisation of disc folding and stacking has been proposed.1 2 On heterologous expression, RDS/peripherin forms stable homo-oligomers or hetero-oligomeric structures with ROM1, another structurally related disc membrane protein.3 4 Whereas RDS/peripherin is expressed in rod as well as in cone photoreceptors, ROM1 expression is restricted to rods.5 6 It is not yet known whether a functional homologue of ROM1 exists in cone photoreceptors.

The role of RDS/peripherin in retinal disease was primarily established in the nds (retinal degeneration slow) mutant mouse, a semidominant inherited form of retinal degeneration characterised by shortened photoreceptor outer segments, progressive photoreceptor loss, and massive accumulation of cell debris at the level of the retinal pigment epithelium.7 8 It has been shown that a 9.2 kb insertion into the mouse RDS/peripherin gene is responsible for the retinal degeneration phenotype in the nds mouse.8 9

The human RDS/peripherin gene has been cloned and localised on human chromosome 6 in the vicinity of a locus for autosomal dominant inherited retinitis pigmentosa (now called RP7).10 11 Consequently, analysis of the human RDS/peripherin gene in patients with retinitis pigmentosa led to the identification of mutations segregating with the disease phenotype in an autosomal dominant fashion.12 13 Analysing a selection of patients with several kinds of retinal degeneration, Wells et al.14 found mutations not only in retinitis pigmentosa patients but also in patients suffering from cone dystrophy, pattern dystrophy, and macular degeneration. This phenotypic variation is not only caused by allelic mutations in the RDS/peripherin gene but expression of the disease is even variable within families,15 a phenomenon now acknowledged to be characteristic of RDS/peripherin gene mutations.

Up to now more than three dozen different mutations in the RDS/peripherin gene have been reported, mostly in pedigrees displaying autosomal dominant inheritance. In some cases, however, digenic inheritance involving both the RDS/peripherin and the ROM1 loci has been suggested.16

We have undertaken a molecular genetic analysis of patients with various forms of central retinal dystrophy in order to determine the prevalence of RDS/peripherin mutations in this group and to contribute to a more complete record of the RDS/peripherin gene mutation spectrum.

Subjects and methods

PATIENTS AND FAMILIES

Patients were seen at the Universitäts-Augenklinik Tübingen or the Augenklinik at the Universitätsklinikum Benjamin Franklin Berlin. Ophthalmological examination included visual acuity and visual field measurement, fundus examination, colour vision testing, dark adaptation curves, ERG recordings, and fluorescein angiography. Inclusion criteria were central or generalised tappetoretinal dystrophy with intrafamilial variability
of disease expression or phenotypes similar to those with reported RDS/peripherin mutations. Patients with the diffuse type of retinitis pigmentosa were excluded. Altogether 76 independent families comprising 138 available patients were subjected to molecular genetic analysis. Diagnoses in index patients included cone dystrophy (19 cases), cone-rod dystrophy (10 cases), macular dystrophy (18 cases), central areolar choroidal dystrophy (nine cases), pattern dystrophy (five cases), rod-cone dystrophy/RP (five cases), and some unclassified tapetoretinal dystrophies (10 cases). Autosomal dominant inheritance was delineated in 29 pedigrees.

DNA ISOLATION AND MUTATION ANALYSIS

DNA was isolated from peripheral venous blood samples using the procedure of Miller et al. Coding and flanking intronic/untranslated regions were amplified from total genomic DNA by means of the polymerase chain reaction. Exon 1 was amplified as two overlapping fragments with primer pairs a (5’ AGCTGTGCTGGGAGCAACGA’a)/a’ (5’ TTCCATCTGGGCGATTCT) and b (5’ TGGCTATCTGTTCTTGAA)/b’ (5’ TCTGCACCCAGGACTG). Exons 2 and 3 were amplified as single fragments with primer pairs c (5’ AAGGCACTTCGAAGCTCT)/c’ (5’ TTACCTTCTACCCCCAGCTG) and d (5’ AGATGGCCCTGTTAAATCTCTCTC)/d’ (5’ GGAGTGCACATTTCCTCAG), respectively. PCR amplified fragments of exons 1 and 2 were subjected to SSCP/heteroduplex analysis on non-denaturing acrylamide gels using a temperature controlled 20 cm vertical gel chamber. Two different electrophoresis conditions were used for each fragment. Conditions varied in gel strength (8%/10% acrylamide), presence/absence of glycerol (10% final concentration), and electrophoresis temperature (room temperature/4°C). Electrophoresis was performed with 6-10 W constant power overnight and gels were silver stained using the procedure of Bassam et al. Samples exhibiting mobility shifts in the SSCP/heteroduplex assay were subjected to DNA sequencing using the solid phase sequencing technology. For DNA sequencing exon 1 was amplified with primer pair FEO168 (5’ GCCCTAAGTCTCCCGGCTT)/FEO167 (5’ CCAATATATCTAGCTCCGACC, 5’ biotinylated), exon 2 with primer pair c (see above)/FEO172 (5’ CTACCCCAAGCTGC-CCAG, 5’ biotinylated), and exon 3 with primer pair FEO174 (5’ GTGGCCACCTCCGGATTCT)/FEO175 (5’ GTAAGTGCTGCCACTCTGT, 5’ biotinylated). PCR products were bound to Dynabeads™ (Dynal) and single stranded DNA was prepared according to protocols recommended by the manufacturer. Single strand DNA (either bound to Dynabeads or the complementary strand) was sequenced with the Single Strand Sequenase Dye Terminator Kit (Applied Biosystems) using primers a, a’, b, b’, c, c’, d, and d’, and analysed on an ABI 373A DNA sequencer. The coding portion of exon 3 of the RDS/peripherin gene was completely sequenced in at least one affected subject in the families under study. Cosegregation analysis within pedigrees was done either by SSCP/heteroduplex analysis, restriction digest analysis, or DNA sequencing as outlined above. In addition, a panel of control subjects was screened either by RFLP analysis with AatII (Gly208Asp, Ser289Leu) or by SSCP analysis (Trp246Arg).

Results

Analysis of exon 1 of the RDS/peripherin gene detected a variant SSCP pattern in pedigree W/K (figs 1 and 2) comprising eight affected family members. Sequence analysis showed a heterozygous C to T transition at nucleotide position (nt) 754 resulting in an arginine to tryptophan substitution at codon 172 (CGG→TGG; Arg172Trp) of the RDS/peripherin gene. Segregation analysis via SSCP and direct DNA sequencing in four affected family members confirmed the presence of the mutation with the disease phenotype in this family (data not shown). The mutation was absent in the spouse and one unaffected daughter of patient III.2. However, one apparently healthy male (IV.2), aged 32, was identified as a gene carrier.

Two other families with the Arg172Trp mutation have previously been described. Thus, Arg172Trp is one of the few RDS/peripherin mutations which allow interfamilial phenotype comparisons. Patients IV.4 and IV.5 in our family present a Stargardt-like clinical picture with symmetrical disciform areas of retinal pigment epithelial (RPE) atrophy and some interspersed patches of choroidal atrophy. However, the foveal RPE is widely intact. These morphological changes correspond with central visual field defects but only mild foveolar sensitivity losses and normal peripheral fields. Visual acuity is normal or slightly reduced. Electoretinography (ERG) shows normal rod and cone signals. Their affected father (III.3) has disciform lesions at the posterior poles consistent with a central areolar choroidal atrophy, central visual field scotomas, and marked loss of visual acuity, but normal ERG recordings. The disease course and the morphological and psychophysical findings in our family closely resemble those reported in two other families with the Arg172Trp mutation, despite the fact that affected persons in these families had abnormal rod and cone ERG signals in later stages of the disease, indicating a more widespread retinal function loss.

In exon 2, five cases with aberrant migration patterns in the SSCP/heteroduplex analysis were observed. Solid phase DNA sequencing of the respective PCR products showed distinct nucleotide sequence alterations in each case, none of which has been reported previously. A heterozygous A to G transition at nt 829 resulting in a lysine to glutamic acid exchange at codon 197 (AAG→GAG, Lys197Glu) was observed in pedigree J (fig 1). Complete cosegregation between the Lys197Glu mutation and the disease was shown by SSCP analysis for four affected and seven unaffected
family members (fig 3). Patients in family Ja suffer from a severe progressive retinal disease with macular dystrophy and widespread functional impairment affecting cone and rod photoreceptors. The diagnosis of cone-rod dystrophy was made.

Both affected sibs investigated in pedigree K/H (fig 1) carry a heterozygous single guanine base insertion at nt 862 or 863 of the RDS/peripherin gene sequence (Gly208insG, fig 2). This frameshift mutation results in a premature translational stop signal eight codons downstream of the insertion. Clinical examination of the patients showed foveal lesions accompanied by small central scotomas and mildly reduced rod and cone ERG amplitudes. Clinical findings were consistent with a pattern type foveal dystrophy. Autosomal dominant inheritance may be suspected although there was no history of visual complaints in the patients’ maternal grandparents (fig 1).

A faint shift in the SSCP pattern was observed in patient III.1 in pedigree Bu (fig 1) who carries a heterozygous G to A transition at nt 963. This results in the replacement of glycine by aspartate residue at codon 208 (GGC→GAC; Gly208Asp). The mutation introduces a new AdrII site which was used to show that the affected mother (II.2) also carries the disease allele (data not shown). There were no medical records available for the maternal grandparents who had died. On ophthalmological examination of patient III.1, central areolar pigment epithelial dystrophy of the retina was diagnosed in both eyes. The Gly208Asp mutation was absent in 75 independent controls.

DNA analysis of exon 2 showed a heteroduplex band but no aberrant SSCP pattern for the single patient in pedigree Ba (fig 2). He harbours a heterozygous C to T mutation at nt 955 which introduces a TAG stop codon for a glutamine residue at codon 239 (CAG→TAG; Glu239ter). A macular pattern dystrophy was diagnosed with fundus changes similar to patients carrying the Gly167Asp and Tyr258ter mutations. No other family member was available for molecular analysis or ophthalmological examination. It was reported that the patient’s sister and daughter do not have any visual problems besides myopia.

Both affected sibs, II.1 and II.5, in family Jo (fig 1) were found to carry a heterozygous T to C change at nt 976 resulting in a replacement of tryptophan by arginine at codon 246 (TGG→CGG; Trp246Arg). However, the clinical picture of these patients is very inconsistent. The brother (II.1) has mild retinitis pigmentosa with visual field constrictions and a history of night blindness, whereas his older sister (II.5) suffers from adult onset vitelliform macular dystrophy with reduced visual acuity and central visual field loss complicated by the development of a subretinal neovascular membrane in one eye. The muta-
Several known polymorphic sequence alterations in exon 3 hamper indirect SSCP/heteroduplex analysis. Therefore, we performed a complete sequence analysis of exon 3 in all 76 families under study. Among them we found two cases with previously unknown mutations in exon 3. Sequence analysis of exon 3 in the patient's sister who suffers from a macular dystrophy, absent in the remaining healthy sibs.

Sequence analysis of exon 3 in the patient (III.1) in pedigree P (fig 1) showed a C to T substitution at nt 1106 resulting in a serine to leucine exchange at codon 428 (TCG → TTG; Ser289Leu). The patient was diagnosed as suffering from a progressive cone dystrophy with central pigment epithelium defects. However, the mutation was not detected in the patient's mother, who was found to suffer from an age related macular dystrophy. Thus, the Ser289Leu mutation found in patient III.1 must result from a de novo event or be inherited from the father for whom no medical history was available. Although this amino acid position is not strictly conserved between species, exclusion of the Ser289Leu mutation from a panel of 55 independent controls supports its association with the observed clinical phenotype.

Table 1 summarises the mutations found in this study in conjunction with the clinical phenotypes observed on ophthalmological examination.

**Discussion**

We have analysed patients from 76 independent pedigrees with various types of mostly central retinal degenerations for mutations in the RDS/peripherin gene. Since combined simultaneous SSCP and heteroduplex analysis was performed under two different gel conditions, and complete sequencing of exon 3 was done for all cases, we assume that mutation detection was achieved with high sensitivity in this study. Indeed, the Glu239ter would have been overlooked from the SSCP pattern alone, but was clearly detectable owing to the formation of a heteroduplex/homoduplex double band (fig 2).
Altogether eight different mutations were found, each occurring in a single family. Thus, mutation screening was positive in 10.6% of all pedigrees, a very high rate for candidate gene analysis in human retinal dystrophies. This indicates that mutations in the RDS/peripherin gene are frequent causes of central retinal dystrophies.

A survey of published reports and databases (OMIM, The Human Gene Mutation Database) for mutations in the RDS/peripherin gene counted about three dozen different mutations reported so far. Seven of the eight mutations described in this paper (Lys197Glu, Gly208InsG, Gly208Asp, Gly239ter, Trp246Arg, Tyr285ter, Ser289Leu) have not been reported previously and thus considerably increase the number of known RDS/peripherin mutations in human retinal diseases. Like the cases reported here the vast majority of known RDS/peripherin mutations are restricted to single pedigrees. These observations reflect the fact that there is a broad allelic spectrum of RDS/peripherin gene mutations, a situation similar to the rhodopsin gene mutations in autosomal dominant retinitis pigmentosa. Although our patients are almost exclusively of central European descent, we did not observe any common disease alleles which would be an indication of mutation hotspots or founder chromosomes.

Except for some clustering at codons 172/173 and codons 208 to 216, RDS/peripherin mutations are spread along the entire coding sequence including all exons. However, more than half of all known mutations are located in the D2 loop segment of the RDS/peripherin polypeptide, which forms an intradiscal extrusion as proposed by the secondary structure model. It has been suggested that the D2 loop is involved in the formation of RDS homo-oligomers or hetero-oligomers with ROM1. These higher order structures may be necessary for disc membrane packaging and stabilisation. The vast majority of known missense mutations in the RDS/peripherin gene are located within the D2 loop. The fact that the D2 loop segment is nearly completely conserved among all known RDS/peripherin sequences supports the notion that missense mutations in the D2 loop have deleterious effects. These mutations may disturb the formation and stability of protein aggregates in the disc membranes.

In our study all patients carried a single heterozygous mutation in the RDS/peripherin gene, which is suggestive of a dominantly inherited trait. With the exception of a few cases where digenic inheritance of mutations in the RDS/peripherin and the ROM1 genes has been assumed, autosomal dominant inheritance has been proposed in pedigrees with mutations in the RDS/peripherin gene. This mode of inheritance could be confirmed by family history and segregation analysis in at least two of our pedigrees (families W/K and Ja, figs 1 and 3). In the other pedigrees, autosomal inheritance could not always be definitely established from the family history. This may be the result of a new mutation event or more

<table>
<thead>
<tr>
<th>Mutations</th>
<th>Pedigree</th>
<th>Phenotype(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg172Trp</td>
<td>W/K</td>
<td>Stargardt's disease (IV.4, IV.5); central areolar choroidal dystrophy (III.3)</td>
</tr>
<tr>
<td>Lys197Glu</td>
<td>Ja</td>
<td>Cone-rod dystrophy</td>
</tr>
<tr>
<td>Gly208InsG</td>
<td>K/H</td>
<td>Pattern dystrophy</td>
</tr>
<tr>
<td>Gly208Asp</td>
<td>Bu</td>
<td>Central areolar pigment epithelial dystrophy</td>
</tr>
<tr>
<td>Gly239ter</td>
<td>Ba</td>
<td>Pattern dystrophy</td>
</tr>
<tr>
<td>Trp246Arg</td>
<td>Jo</td>
<td>Retinitis pigmentosa (II.1)/ adult onset vitelliform macular dystrophy (II.5)</td>
</tr>
<tr>
<td>Tyr285ter</td>
<td>R</td>
<td>Pattern dystrophy</td>
</tr>
<tr>
<td>Ser289Leu</td>
<td>P</td>
<td>Cone dystrophy</td>
</tr>
</tbody>
</table>

Table 1 Observed RDS/peripherin gene mutations and their corresponding phenotypes

Specific patients are shown in brackets.
likely because of the variable expression of the disease phenotype which leads to gene carriers without any subjective visual complaints. Subjects IV.2 in family W/K and III.3 and III.5 in family Jo may be taken as examples of such mild phenotypic expression. Furthermore, for Gly208Asp, Trp246Arg, and Ser289Leu, we could rule out the possibility of common RDS gene polymorphisms (>1%).

Three of the mutations reported in this paper, Gly208InsG, Gin239ter, and Tyr289ter, lead to premature translational termination. Moreover, about one third of all known RDS/peripherin mutations are either nonsense substitutions or out of frame insertions/deletions which therefore may represent null alleles. 14 22-23 The deleterious effect of functional hemizygosity may be explained by the inability to compensate for a reduced gene dosage. 24 Haplo-insufficiency has also been proposed to account for the semidominant acting molecular defect in the rdS mouse where a 9.2 kb insertion into exon 2 disrupts the RDS/peripherin reading frame.

However, it is obvious that a simple gene dosage model cannot explain the highly variable phenotypes associated with potential null alleles of the RDS/peripherin gene. Intrafamilial variability in clinical expression suggests that other genetic or environmental factors may determine the actual type and course of the disease in a person. It has been shown that in some families with digenic inherited retinitis pigmentosa only simultaneous mutations in the RDS/peripherin and the ROM1 gene are sufficient to cause retinal degeneration. 15 Consequently, it may be reasoned that in cases where a RDS/peripherin mutation alone is sufficient to account for a clinical phenotype, the actual sequence and allelic composition of ROM1 and of other as yet unidentified structural elements may moderate the disease expression.

Taken together, the observations from mutation analysis argue for two different pathogenic mechanisms of RDS/peripherin mutations: missense mutations in the D2 loop may interfere with the formation of functional higher order homo- or hetero-oligomeric protein structures, whereas a gene dosage effect may act in the case of probable null alleles. Gene and protein expression analysis of patients or in appropriate in vitro systems will be necessary to elucidate further the molecular pathogenicity of RDS/peripherin gene mutations.

We would like to thank Drs Klaus Rüther, UF Kretschmann, and Drs Ulf Molday and Stefan Molday for their support and for valuable comments and correction of the manuscript. This work was supported by grants from the Deutsche Forschungsgemeinschaft (WII 1189/1-2, Ru577/1-3, Ke 442/7-1, and Z17-3).

27 Kajiwara K, Sandberg MA, Berson EL, Dryja TP. A null mutation in the human peripheral/RDS gene in a family
RDS/peripherin gene mutations are frequent causes of central retinal dystrophies.

S Kohl, M Christ-Adler, E Apfelstedt-Sylla, U Kellner, A Eckstein, E Zrenner and B Wissinger

*J Med Genet* 1997 34: 620-626
doi: 10.1136/jmg.34.8.620

Updated information and services can be found at:
[http://jmg.bmj.com/content/34/8/620](http://jmg.bmj.com/content/34/8/620)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)